LEO Pharma has gained marketing authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its topical pan-Janus kinase (JAK) inhibitor, Anzupgo (delgocitinib ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine givinostat (Duvyzat) of Italfarmaco to treat Duchenne muscular ...

The new marketing authorisation was granted on 31st December ... of treatments and if those treatments did not work or are no longer working. Julian Beach, MHRA Interim executive director of ...

and will be immediately available in England for eligible patients following marketing authorisation from the MHRA. This follows the initial licence for treatment of patients with non-metastatic ...

The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Commission (EC) have approved a change to the terms of the marketing authorisation for LEO Pharma’s Adtralza ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Jeraygo (aprocitentan) to treat hypertension (high blood pressure) in adults whose blood pressure cannot be adequately ...

For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication ...

and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) for the treatment of wet age-related macular degeneration (wet AMD).

announced today it has received clinical trial authorisation (CTA) from the UK’s MHRA (Medicines and Healthcare products Regulatory Agency) for its lead candidate, PTD802. A selective GPR17 (G ...